RECIP 1.0联合PSA评估接受225Ac/177Lu-PSMA联合治疗的mCRPC患者的疗效反应
本研究在25例接受225Ac/177Lu-PSMA联合治疗(ALCT)的mCRPC患者中评估RECIP 1.0及RECIP联合PSA的疗效反应参数。RECIP-PR、RECIP-SD、RECIP-PD分别为48%、36%、16%,RECIP联合PSA反应者14/25(56%)。RECIP联合PSA反应者总生存显著长于进展者(p=0.049)。作者认为ALCT是有前景的治疗方案,结果支持进一步研究RECIP联合PSA作为疗效评估和总生存预测工具。
要点
- 25例mCRPC患者接受ALCT,RECIP-PR 12/25(48%)、RECIP-SD 9/25(36%)、RECIP-PD 4/25(16%)。
- RECIP联合PSA反应者14/25(56%),进展者8/25(32%)。
- RECIP联合PSA反应者总生存显著长于进展者(p=0.049)。
核心结论
- ALCT是有前景的治疗方案,可能延长在[177Lu]Lu-PSMA放射性配体治疗期间进展患者的生存。
- 作者认为结果支持进一步研究RECIP联合PSA作为ALCT治疗下mCRPC的疗效评估和总生存预测工具。
研究设计与样本
- 评估接受225Ac-/177Lu-PSMA联合治疗(ALCT)患者的临床和影像学疗效反应参数,共25例。
主要发现
- RECIP 1.0评估:完全缓解(RECIP-CR)0/25(0%)、部分缓解(RECIP-PR)12/25(48%)、疾病稳定(RECIP-SD)9/25(36%)、疾病进展(RECIP-PD)4/25(16%)。
- RECIP联合PSA反应者14/25(56%),RECIP联合PSA进展者8/25(32%)。
- 视觉RECIP的评估者间信度较高(κ=0.757,p<0.001),视觉与定量RECIP之间几乎完全一致(κ=0.879,p<0.001)。
- 四种不同治疗方案之间总生存无显著差异(p>0.05)。
- PSA下降/稳定组与PSA进展组之间总生存无显著差异(p=0.312);无RECIP进展(RECIP-PR+RECIP-SD)组与RECIP进展(RECIP-PD)组之间中位总生存无显著差异(p>0.05)。
关键数值与推荐
- RECIP 1.0分类:RECIP-CR 0/25(0%)、RECIP-PR 12/25(48%)、RECIP-SD 9/25(36%)、RECIP-PD 4/25(16%)。
- RECIP联合PSA:反应14/25(56%),进展8/25(32%)。
- 视觉RECIP评估者间信度κ=0.757(p<0.001);视觉与定量RECIP一致性κ=0.879(p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Targeted alpha therapy (TAT) with 225Ac has shown promising results in metastatic castration-resistant prostate cancer (mCRPC) patients pre-treated with [177Lu]Lu-PSMA radioligand therapy (RLT). A combination treatment regimen adding 177Lu to decreased 225Ac activities may improve toxicity profile while maintaining sufficient anti-tumor effect. We therefore evaluated clinical and image-based response parameters in patients treated with 225Ac-/177Lu-PSMA combination therapies (ALCT). RESULTS: Complete response (RECIP-CR), partial response (RECIP-PR), stable disease (RECIP-SD), progressive disease (RECIP-PD) according to RECIP 1.0 was observed in 0/25 (0%), 12/25 (48%), 9/25 (36%) and 4/25 (16%) patients, respectively. Response by RECIP + PSA was observed in 14/25 (56%) patients and progression by RECIP + PSA in 8/25 (32%) patients. Interrater reliability for visual RECIP was substantial (κ = 0.757, p < 0.001), while agreement between visual and quantitative RECIP was almost fully congruent (κ = 0.879, p < 0.001). OS did not significantly vary among the four different therapy regimens (p > 0.05). When grouping patients with declining / stable PSA as responders, these patients showed no significant difference in overall survival compared to patients with progressive PSA after ALCT (p = 0.312). Similarly, there was no significant difference in median overall survival between patients without RECIP-progression (RECIP-PR + RECIP-SD) and patients with RECIP-progression (RECIP-PD) (p > 0.05), but when applying the composite classification, RECIP + PSA responders survived significantly longer compared to patients with RECIP + PSA progression (p = 0.049). CONCLUSIONS: ALCT is a promising therapeutic regimen that may prolong survival in patients who progress during [177Lu]Lu-PSMA RLT. Our results motivate to further investigate the use of RECIP + PSA as tool for response assessment and for overall survival prediction in mCRPC under ALCT.
引用
- Sheikh GT, Delker A, Zacherl MJ, et al. RECIP 1.0 + PSA for response assessment in mCRPC patients treated with 225Ac / 177Lu PSMA combination therapy. EJNMMI Res. 2025. PMID: 40038098. doi:10.1186/s13550-025-01211-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。